The Cardiovascular Effects of Alcohol Consumption: Dose-Response Relationships and Beverage Type Differences

心血管疾患心血管疾患とは、心臓発作、脳卒中、下肢の動脈閉塞など、心臓や血管に関する問題の総称です。. (CVD) remains the leading cause of morbidity and mortality globally, necessitating a rigorous evaluation of modifiable 危険因子危険因子とは、高コレステロール粒子、高血圧、喫煙、糖尿病、家族歴など、病気にかかる可能性を高めるものです。., among which アルコールアルコールは、ビール、ワイン、蒸留酒を酔わせる成分です。. consumption occupies a uniquely controversial position.[1] For decades, the medical community has observed a persistent J-shaped or U-shaped association in epidemiological data, wherein light-to-moderate consumers appear to have a lower risk of 冠動脈疾患冠状動脈疾患は、アスケロスクレロティック・プラーク（動脈硬化性プラーク）の蓄積によって心筋に血液を供給する動脈が狭窄または閉塞する疾患であり、世界中で心筋梗塞および心臓死の主要な原因となっています。. (CHD) and 虚血性脳卒中虚血性脳卒中は、脳の一部への血流が遮断され、脳組織が壊死し始めることで起こります。. compared to both abstainers and heavy drinkers.[1] This observation, frequently termed the “cardioprotective effect,” has been attributed to a variety of physiological mechanisms, including favorable shifts in 脂質プロファイル総コレステロール、LDLコレステロール、HDLコレステロール、中性脂肪を測定する血液検査のパネルで、心血管リスクの評価や食事療法・薬物治療の効果のモニタリングに使用される。., improved インスリン感受性インスリン感受性とは、細胞がインスリンに対してどれだけよく反応するかということです。それはインスリン抵抗性の反対です。., and anti-clotting effects.[2] However, recent advancements in genetic 流行病学Epidemiology is the study of health patterns in large groups of people — who gets sick, where, and what they had in common.—most notably メンデルランダム化Mendelian randomization is a clever research method that uses the genes people were born with as a natural experiment.—and more robust adjustments for 交絡Confounding is when a hidden third factor makes two unrelated things look connected. variables have begun to challenge the validity of this perceived benefit.[3,4] This report provides an exhaustive analysis of the 用量反応関係A dose-response relationship describes how the magnitude of a biological effect changes as the amount of an exposure (such as weekly exercise minutes) increases; in this article, resistance training shows a non-linear dose-response for mortality, with benefits plateauing around 120 minutes per week and a J-shaped curve emerging at very high volumes in older women. between alcohol and cardiovascular health, differentiating between beverage types, exploring underlying biological mechanisms, and evaluating the net clinical impact on mortality and population-specific risks.[1]

Metabolic Pathways and the Biochemistry of Ethanol

The cardiovascular impact of alcohol begins with its metabolic transformation in the liver and subsequent interaction with systemic tissues.[2] Ethanol is primarily oxidized via a two-step enzymatic process.[2] First, alcohol dehydrogenase (ADH) converts ethanol into acetaldehydeアルコール脱水素酵素が肝臓でエタノールを分解する際に生成される、非常に反応性が高く毒性の強い中間体。アセトアルデヒドは酸化ストレスを促進し、細胞結合を損傷し、特にアルデヒド脱水素酵素の活性が低下している個人において、直接的な心臓毒性作用を発揮する。., a highly reactive and toxic metabolite.[2] Second, aldehyde dehydrogenase (ALDH) converts acetaldehyde into acetate, a relatively benign substance that is eventually broken down into carbon dioxide and water.[2]

The efficiency of this pathway is a critical determinant of individual susceptibility to alcohol-related harm.[5] In populations with high frequencies of the ALDH2アルデヒド脱水素酵素2をコードする遺伝子は、有毒なエタノールの代謝産物であるアセトアルデヒドを無害な酢酸に変換します。東アジア人に多く見られるALDH2*2バリアントを持つ個体では、酵素活性が低下しており、飲酒時にアセトアルデヒドの蓄積、フラッシング反応、および心臓毒性のリスク増加を引き起こします。.*2 allele, particularly in East Asia, the second step of metabolism is impaired, leading to the accumulation of acetaldehyde.[5] This accumulation results in the “flushing syndrome” characterized by facial erythema, tachycardia, and nausea, and serves as a natural deterrent to heavy consumption.[5] However, for those who continue to drink despite this genetic predisposition, the elevated levels of acetaldehyde exert direct cardiotoxic effects, promoting 酸化ストレス酸化ストレスとは、有害な活性分子と、それらを中和する身体の能力との間の不均衡です。. and damaging cellular junctions.[5-7]

The metabolic process also significantly alters the cellular redox state.[2] The conversion of ethanol and acetaldehyde requires the reduction of nicotinamide adenine dinucleotide (NAD+) to NADH.[2] The resulting increase in the NADH/NAD+ ratioA measure of the cellular redox state reflecting the balance between the reduced (NADH) and oxidized (NAD+) forms of nicotinamide adenine dinucleotide; ethanol metabolism raises this ratio in liver cells, suppressing gluconeogenesis and shifting hepatic metabolism toward fatty acid synthesis, which contributes to hypertriglyceridemia and may accelerate atherosclerosis in heavy drinkers. suppresses gluconeogenesis and shifts hepatic metabolism toward fatty acid synthesis, contributing to hypertriglyceridemia and potentially accelerating the early stages of 動脈硬化動脈硬化は、ほとんど的心筋梗塞と多くの脳卒中の背景にある病気です。コレステロールの粒子が動脈の壁に入り込み、体がそれを掃除するために免疫細胞を送り込み、何年もかけてその堆積物が硬化してプラークになります。. in heavy drinkers.[2]

Dose-Response Relationships: The J-Shaped Curve Re-evaluated

Central to the discussion of alcohol and cardiovascular health is the definition of consumption levels and the standard drink.[8] In the United States, a standard drink contains approximately 14 grams of pure ethanol, though international definitions vary.[8]

Consumption Category	Definitions (Standard Drinks/Day)	Typical Ethanol Equivalent (g/day)
Low Consumption	< 1 drink/day	< 14g
Moderate Consumption	1–2 drinks/day (Men), 1 drink/day (Women)	14g – 28g
High/Heavy Consumption	> 3–4 drinks/day or Binge episodes	> 42g
Binge Drinking	>= 5 (Men) or >= 4 (Women) in ~2 hours	>= 70g

Observational Evidence for Cardioprotection

Traditional 前向きコホート前向きコホート研究は、健康な人々を登録し、その特徴を記録し、その後何が起こるかを待って観察する。. studies have consistently identified a J字型曲線A statistical pattern in epidemiological data where light-to-moderate consumers of alcohol appear to have lower cardiovascular risk than both abstainers and heavy drinkers, producing a curve shaped like the letter J when risk is plotted against consumption level; the validity of this pattern has been increasingly challenged by Mendelian randomization studies and better adjustment for confounding. for various cardiovascular outcomes.[1] A recent メタ分析メタアナリシスは、多数の個別研究の結果を統計的に統合して1つの全体的な推定値を算出します。. of observational data indicated that moderate drinkers experience a 12% lower risk of 心筋梗塞詳しい項目については心臓発作をご覧ください。. (RR = 0.88) and an 11% lower risk of total 脳卒中脳卒中は、脳の一部への血流が詰まりまたは出血によって止まるときに起こります。. (RR = 0.89) compared to never-consumers.[1,9] This numeric alignment is important: an RR of 0.88 corresponds to a 12% relative reduction, not a 22% reduction, and careful reporting of effect sizes prevents overstatement while preserving interpretability across outcomes.[1,9] The nadir of this curve, representing the lowest risk, is typically observed at consumption levels of approximately 1 to 2 drinks per day for coronary heart disease and <= 1 drink per day for stroke mortality.[1]

Methodological Bias and Causal Inference

The perceived protective effect of moderate drinking is increasingly scrutinized due to several endemic biases in observational research:[1]

1. Sick Quitter BiasA form of selection bias in alcohol research in which former drinkers who stopped due to illness are grouped with lifelong abstainers, making the non-drinking reference group appear unhealthier than it truly is and artificially inflating the apparent benefit of moderate drinking.: Former drinkers, who may have abstained due to alcohol-related health issues or medications, are often grouped with life-long abstainers. This makes the “moderate” drinking group appear healthier by comparison.[1]
2. Healthy User BiasA confounding phenomenon in which moderate drinkers tend to have higher socioeconomic status, better diets, and more active lifestyles, making alcohol appear protective when it may simply be a marker for other health-promoting behaviors.: Moderate alcohol consumption is often a marker for higher socioeconomic status, better dietary habits (such as the 地中海式ダイエットThe Mediterranean diet emphasizes vegetables, fruit, beans, whole grains, nuts, and olive oil, with fish and little red meat.), and increased physical activity—all of which independently reduce cardiovascular risk.[1]
3. Underreporting: Self-reported data often underestimate actual intake, potentially leading to the misclassification of heavy drinkers as moderate ones.[2]

メンデルの ランダム化無作為化とは、臨床試験の参加者を偶然によって治療群または対照群に割り当てるプロセスであり、既知および未知の交絡因子が均等に分散されることを保証するものです。しかし、PREDIMEDの研究で監査人が発見したように、無作為化が失敗した場合、両群間には治療効果の見かけを歪めるような違いが生じる可能性があります。. (MR) studies, which use genetic variants like ADH1Bエタノール代謝の最初のステップを担う酵素であるアルコールデヒドロゲナーゼ1Bをコードする遺伝子。ADH1Bの遺伝子変異（特にrs1229984）はアルコールが分解される速度に影響を与え、アルコールと心血管リスクに関するメンデルランダム化研究において、一般的に操作変数として用いられる。. (rs1229984) and ALDH2 (rs671) as instrumental variables, have provided a different perspective.[3,4] Because alleles are randomly assigned at conception, they are less prone to the lifestyle 交絡因子A confounder is a variable that is associated with both the exposure being studied (such as TMAO) and the outcome (such as heart disease), making it appear as though one causes the other when a third factor is actually responsible. The article lists renal function, insulin resistance, systemic inflammation, and age as major confounders that inflate the apparent cardiovascular risk of high TMAO in… that plague observational studies.[3,4] Large-scale MR analyses, including data from the ミリオン・ベテラン・プログラムThe Million Veteran Program is a large US biobank and genomic research initiative drawing on veterans' health data; genetic analyses from this cohort have been used to identify causal relationships between ApoB-raising gene variants and conditions such as peripheral artery disease. そして UKバイオバンクUK Biobank holds detailed genetic, lifestyle, and health data on half a million British volunteers, linked to their medical records., have largely failed to support the protective effect.[3,4] Instead, they often demonstrate a linear increase in risks for 高血圧Hypertension is the medical term for high blood pressure. そして 冠動脈疾患冠状動脈疾患は、心筋に栄養を送る動脈にプラークが蓄積する病気です。. across all levels of alcohol consumption, suggesting that any benefit observed in traditional studies is likely non-causal.[3,4]

Alcohol and the Pathogenesis of Atherosclerosis

Atherosclerosis, the thickening and hardening of arterial walls due to 歯垢プラークとは、動脈の壁の内側にコレステロール、免疫細胞、瘢痕組織、カルシウムが蓄積したものです。. accumulation, is the underlying cause of most cardiovascular events.[2] Alcohol’s effect on this process is multi-factorial, involving lipids, inflammatory markers, and 血管内皮機能血管の内側を覆う内膜が血管の緊張、炎症、血液凝固を調節する能力。健康な内視細胞は一酸化窒素を放出し、動脈をリラックスさせ、プラーク形成に対する抵抗力を保ちます。..[2]

Lipids and Lipoproteins

One of the most robust observational findings is the positive association between alcohol intake and high-density リポタンパク質リポタンパク質とは、脂肪とコレステロールを血流に乗せて運ぶ小さなカプセルのことです。脂肪は水に溶けないため、移動するにはタンパク質の包みが必要です。. (HDLHDL、すなわち高密度リポタンパク質は、しばしば「善玉コレステロール」と呼ばれる粒子です。組織からコレステロールを回収し、肝臓へ運び戻します。.) コレステロールコレステロールは、体が必要とするロウ状の物質です。細胞壁、ホルモン、ビタミンD、そして食べ物を消化する胆汁の材料となります。コレステロールがなければ私たちは生きていけません。..[2] Ethanol increases the production of アポリポプロテインアポリポ蛋白とは、血液中の脂肪を運ぶ粒子に結合しているタンパク質です。脂肪と水は混ざらないため、これらのタンパク質は脂肪が血流の中を安全に移動できるようにする包みのような役割を果たします。. A-I and A-II and the transport rate of HDL subfractions.[2]

Lipid Parameter	Effect of Moderate Alcohol	Effect of Heavy Alcohol
HDL Cholesterol	Increase (HDL2 and HDL3)	Significant Increase
LDL CholesterolLDLコレステロール（LDL-C）は、LDL粒子内に存在するコレステロールの量です。これは、ほとんどすべての標準的な検査報告書に記載されている数値です。.	Slight decrease or No change	Variable; possible increase
トリグリセリドトリグリセリド（中性脂肪）は、血液中および体内の蓄積脂肪の主要な形態です。.	Minimal effect	Significant increase
Apolipoprotein A-IApolipoprotein A-I is the main structural protein of HDL particles, roughly the HDL equivalent of what ApoB is for the harmful ones.	Increase	Significant increase

While HDL has historically been considered “good” cholesterol, the alcohol-induced increase in HDL does not necessarily translate into a reduction in cardiovascular risk.[3,4] Mendelian randomization studies have shown that increasing HDL through alcohol does not have a clear causal link to reduced myocardial infarction risk, suggesting that the functional quality of the HDL particles or the pathways involved may be more important than the absolute concentration.[3,4]

Inflammation and Biomarkers

Low-grade systemic 炎症炎症は、怪我や侵入物とみなしたものに対する免疫システムの反応です。これにより腫れや熱、そして浄化細胞がもたらされます。. is a critical driver of atherosclerotic progression.[2] Moderate alcohol consumption has been associated with lower levels of C反応性タンパク質C反応性タンパク（CRP）は、体内のどこかで炎症が起きているときに肝臓が産生する物質です。この検査の高感度バージョンであるhs-CRPは、心疾患のリスクを評価するために使用されます。. (CRP), fibrinogen, and Interleukin-6 (IL-6)プラークの炎症時にIL-1βへの反応として産生され、肝臓へと移動してCRP産生を刺激するシグナル伝達タンパク質。したがって、血中IL-6の上昇は活動性の血管炎症を反映する。. in observational studies.[2] However, the causal nature of these associations is questionable.[20,21] One-sample and two-sample MR analyses have suggested that while CRP is a strong predictive marker for ischemic stroke and death, it does not have a causal role in these outcomes.[20] Similarly, genetic evidence suggests that the relationship between alcohol and inflammation markers may be confounded by factors like 喫煙喫煙は血管の内壁を傷つけ、血圧を上げ、血液を凝固しやすくし、プラークの成長を早めます。. そして ボディ質量指数ボディ・マス・インデックス（BMI）とは、身長と体重から計算される数値であり、体格の大まかな目安として使用されます。., and by correlated health behaviors that cluster with beverage choice and drinking pattern.[21]

Endothelial Function and Imaging

Healthy endothelial function is essential for vascular homeostasis, mediated primarily through 一酸化窒素一酸化窒素は、血管の内壁が血管に弛緩して広がるよう伝えるために産生するガスです。. (NO) production.[2] Moderate intake, particularly of red wine, has been shown to acutely improve flow-mediated vasodilation (FMD).[22] In contrast, chronic heavy drinking impairs endothelial function, promotes oxidative stress, and contributes to arterial stiffening.[2]

Imaging studies provide an objective look at 無症候性動脈硬化症Subclinical atherosclerosis means plaque is present but has not yet caused any symptoms or events..[10,11] The relationship between alcohol and carotid intima-media thickness (cIMT)Carotid intima-media thickness is an ultrasound measurement of the combined thickness of the inner two layers of the carotid artery wall in the neck; a faster rate of thickening indicates accelerating atherosclerosis, and it is used as a surrogate marker for cardiovascular risk in trials such as ELITE. または 冠動脈石灰化（CAC）冠動脈カルシウムは、冠動脈壁における石灰化プラークの沈着の測定値であり、CTスキャンで定量化されアガトストン・スコアとして表されます。スコアが高いほど、累積プラーク負荷が大きいことを示し、将来の心血管イベントを予測します。. scores remains inconsistent.[10,11] While some Japanese studies have found lower cIMT in moderate drinkers compared to never-drinkers, larger consortia like the USE-IMT have reported more complex, often null, associations after adjusting for cardiovascular risk factors.[10] A 縦断研究曝露や特性が数年または数十年後の死亡率などの結果とどのように関連しているかを観察するために、長期間にわたって同じ個人を追跡する研究デザイン。. in Sweden found no association between midlife alcohol intake and the presence of carotid plaque or IMT at age 60, further suggesting that the atherosclerotic benefits of alcohol may be overstated and may reflect selection and residual confounding rather than durable plaque-level protection.[11]

Cardiac Arrhythmogenesis: Atrial Fibrillation and Beyond

While alcohol may have mixed effects on coronary disease, its role as a pro-arrhythmic agent is well-established.[12,28] The most common arrhythmia associated with alcohol use is 心房細動Atrial fibrillation, often shortened to AFib, is a fast and irregular heartbeat that starts in the upper chambers of the heart. (AF).[12,28]

Atrial Fibrillation and the “Holiday Heart”

The association between heavy alcohol consumption and new-onset AF, often occurring after binge episodes, is known as “Holiday Heart SyndromeThe phenomenon in which binge alcohol consumption triggers acute atrial fibrillation or other arrhythmias, classically observed after holiday celebrations; it demonstrates that even isolated episodes of heavy drinking can destabilize the heart's electrical system without requiring underlying structural disease.”.[28] However, even moderate consumption is linked to a heightened risk.[12,15] Meta-analyses of over 10 million participants show that for every additional drink per day (often modeled as ~12 g ethanol/day increments), the risk of AF increases by approximately 6% to 8%.[9,12]

パラメータ	Impact of Alcohol on AF Risk
Dose-ResponseA dose-response relationship means more of something produces more of an effect, in a consistent gradient.	Linear in men; potentially J-shaped in women
Risk per Drink	6% – 8% increase per ~12g ethanol/day
Binge Drinking	Significant acute trigger for episodes
Recurrence	Alcohol abstainers have lower recurrence after ablation

Electrophysiological and Structural Mechanisms

The mechanisms by which alcohol induces AF are both acute and chronic:[28,29,31]

1. Electrophysiological Changes: Alcohol acutely shortens the effective refractory period (ERP)The minimum time interval after an electrical impulse during which cardiac tissue cannot be re-stimulated; alcohol acutely shortens the atrial ERP, particularly in the pulmonary veins, making the heart more susceptible to the re-entrant electrical circuits that underlie atrial fibrillation. of the atria, particularly in the pulmonary veins, making the heart more susceptible to re-entrant circuits.[28]
2. Structural Remodeling: Chronic consumption is associated with left atrial enlargementStructural expansion of the left atrium of the heart, associated with chronic alcohol consumption; the enlarged and remodeled atrium develops low-voltage zones (fibrotic areas) that act as substrates sustaining persistent atrial fibrillation. and the development of low-voltage zones (fibrosis), which serve as substrates for persistent AF.[28]
3. Autonomic Nervous System: Alcohol stimulates the sympathetic component while reducing heart rate variabilityHeart rate variability (HRV) is the natural beat-to-beat variation in the time between heartbeats, and is used as a non-invasive measure of autonomic nervous system balance — higher variability generally reflecting greater parasympathetic (rest-and-digest) activity. It is listed in the article as one of the outcomes measured in meditation trials., creating a state of autonomic imbalance that favors arrhythmias.[28]
4. Ion Channel Modulation: Ethanol and acetaldehyde can disrupt L-type calcium channels and sodium channels, leading to intracellular calcium imbalance and electrical instability.[29]

Cerebrovascular Risk: The Stroke Subtype Dichotomy

The impact of alcohol on stroke is highly heterogeneous and depends heavily on the subtype (ischemic vs. hemorrhagic) and the pattern of drinking.[1,23]

Ischemic Stroke

Observational meta-analyses often report a J-shaped relationship for ischemic stroke.[1,23] Moderate drinkers (1–2 drinks/day) show a reduced risk (RR = 0.83 to 0.87), whereas heavy drinkers experience a significant increase in risk (RR = 1.31).[1,23] The perceived benefit at lower doses is thought to be mediated by alcohol’s anti-thrombotic properties, including reduced fibrinogen levels and decreased platelet reactivity.[2,24] However, MR studies using the ADH1B variant suggest that any reduction in alcohol intake is associated with a reduced risk of ischemic stroke, implying that the “cardioprotective” observational findings may be due to selection bias.[3,4]

Hemorrhagic Stroke

In stark contrast, the relationship between alcohol and 脳出血A hemorrhagic stroke is a type of stroke caused by bleeding into or around the brain rather than by a blocked artery; because aspirin impairs clotting, it raises the risk of this complication, which is a key reason its use in low-risk individuals is now discouraged. appears to be more linear.[1,23] Current alcohol consumers have approximately a 14% increased risk for hemorrhagic stroke compared to nondrinkers, a risk that increases steadily with the amount consumed.[1,23] This is likely driven by alcohol’s effect on 血圧血圧とは、血液が動脈の壁を押す力ののことです。120/80のように2つの数字で表されます。上の数字は心臓が収縮するときの圧力で、下の数字は弛緩するときの圧力です。. and its impairment of primary hemostasis.[2] Binge drinking, in particular, causes transient but sharp increases in blood pressure that can trigger acute intracerebral hemorrhage.[2]

Myocardial Structure and Alcoholic Cardiomyopathy

Chronic heavy alcohol consumption can lead to alcoholic cardiomyopathy (ACM)持続的なエタノール毒性により心筋が弱って拡大する、慢性的な多量飲酒（通常、少なくとも5年間にわたり毎日約80グラムのエタノール摂取と定義される）によって引き起こされる拡張型心筋症の一形態。多くの心不全の原因とは異なり、アルコール性心筋症は持続的な禁酒によって大幅に改善することが多い。., a form of non-ischemic dilated 心筋症Cardiomyopathy is disease of the heart muscle itself, rather than of the arteries feeding it. characterized by ventricular dilation and impaired systolic function.[14,15]

Thresholds and Pathophysiology

ACM typically develops after long-term exposure to high levels of ethanol.[14,15] While definitions vary, the classic threshold is often cited as the consumption of more than 80 grams of ethanol per day for at least five years.[14,15] This condition accounts for a clinically meaningful fraction of non-ischemic dilated cardiomyopathies, although the exact proportion varies widely by cohort, ascertainment method, and exposure definition, and reported estimates can span broad ranges across clinical series and population studies.[15]

The pathogenesis of ACM involves:

• 直接的な有害性： Ethanol and acetaldehyde induce oxidative stress, impairing タンパク質タンパク質は、体内の筋肉や組織の構築と修復に使用される栄養素です。. synthesis and causing mitochondrial dysfunction in cardiomyocytes.[15]
• Activation of the Renin-Angiotensin System: Chronic use stimulates neurohormonal pathways that promote myocardial fibrosis and remodeling.[15]
• Nutritional Deficiencies: While alcohol is a primary toxin, secondary factors like thiamine deficiency (Beriberi) can exacerbate cardiac dysfunction in some patients.[14,15]

Reversibility and Prognosis

A defining characteristic of ACM is its potential for reversibility.[14,15] Unlike idiopathic dilated cardiomyopathy, ACM often shows significant improvement in 左室駆出率心臓の主なポンプ室から1回の拍動ごとに送り出される血液の割合。正常値は55%以上であり、心疾患後の駆出率の上昇は心機能回復の測定可能な兆候である。. (LVEF) and clinical symptoms upon total abstinence from alcohol.[15,25] Even in patients with advanced disease, early intervention and cessation of drinking can lead to a favorable prognosis and stabilization of 心不全心不全とは、心臓が体の要求を満たすのに十分なほど血液を送り出せない状態を指します。心不全という名前は誤解を招きやすいですが、心臓が停止したという意味ではありません。..[15,25]

Beverage Type Comparison: Wine, Beer, and Spirits

A persistent question in cardiovascular research is whether the type of beverage consumed matters.[16,18] 「“フレンチ・パラドックスThe French Paradox is the observation that France had relatively low coronary heart disease mortality in the 1980s and 1990s despite high saturated fat consumption; analyses have attributed this apparent paradox to a time-lag in France's adoption of high-fat diets compared with other Western nations, systematic under-certification of CHD deaths by French physicians, and the cumulative nature of a…” popularized the idea that red wine, in particular, offers unique protection due to its high concentration of ポリフェノールポリフェノールは抗酸化作用を持つ植物由来の化合物の総称であり、エキストラバージンオリーブオイルにはこれが特に豊富に含まれています。ハードな心血管エンドポイントを測定した臨床試験では意味のある臨床的利益は確認されていないものの、精製オリーブオイルよりも保護効果が高い可能性がある理由として、ポリフェノールがしばしば挙げられます。. like resveratrol.[22]

Wine vs. Beer vs. Spirits

Meta-analyses of beverage types suggest that wine drinkers often have the lowest 相対リスク相対リスクは2つのグループを比較するもので、このグループの心臓発作の発生率は、あのグループよりも30パーセント低かった。. for cardiovascular mortality, followed by beer, with spirits often showing a null or less favorable effect, although the magnitude of these differences is highly sensitive to confounding control, socioeconomic patterning, and smoking-related covariation.[18]

Beverage Type	Observational Relative Risk (CVD Mortality)	Proposed Beneficial Mechanism
Wine (Red)	0.73	Polyphenols, Resveratrol, 抗酸化物質抗酸化物質とは、体内にある有害な分子を取り除く物質です。ビタミンEやベータカロテンはその例です。. effects
Beer	0.80	Ethanol, Vitamin B, Hops-derived compounds
Spirits	0.98 (Neutral to High)	Primarily Ethanol-mediated effects

These estimates should be interpreted as observationally associated risks rather than causal pharmacologic effects; across datasets, effect sizes may shift toward null after fuller adjustment for diet quality, income, healthcare access, and smoking intensity, and the “wine advantage” can shrink materially when beverage choice is treated as a behavioral cluster rather than an isolated exposure.[18]

The Polyphenol Controversy

Experimental studies have demonstrated that red wine polyphenols can enhance NO bioavailability, reduce oxidative stress, and inhibit platelet aggregation more effectively than ethanol alone.[22] Some studies using dealcoholized red wine have shown that these vascular benefits can be achieved without the harmful effects of ethanol.[22]

However, the epidemiological “wine advantage” is likely heavily confounded.[18] Wine drinkers consistently buy healthier foods, have higher socioeconomic status, and are less likely to smoke compared to beer or spirit drinkers.[18] When studies are meticulously adjusted for these factors, the difference between wine and other beverage types often diminishes, suggesting that the ethanol component and the associated lifestyle may be the primary drivers of any observed benefit.[18]

Mortality Outcomes and Global Burden

The cardiovascular effects of alcohol must be situated within the broader context of global health and 全因死亡率全死因死亡とは、心疾患に限らず、あらゆる原因による死亡を意味し、研究が測定できる最も広範で、ごまかしが最も効かない結果です。..[17,27]

Cardiovascular vs. All-Cause Mortality

While moderate consumption may be associated with reduced cardiovascular mortality in some observational cohorts (RR = 0.82), this benefit is often offset by increases in other causes of death, particularly cancer and accidents.[1] The 2021 Global Burden of Disease (GBD) study highlights that alcohol use remains a top risk factor for global disease burden, ranking as the 10th leading risk factor for all deaths and the number one risk factor for those aged 15–49.[27]

年齢層	心血管系への影響	Overall Health Impact
Ages 15–39	No health benefits; primarily risks	Significant risk of injury and acute events
Ages 40–64	Mixed; potential protective association	High cancer risk; offset mortality benefit
Ages 65+	Observational protective effects for CVD	Potential benefit; debated by 遺伝学Genetics is the study of what you inherit from your parents.

Recent Trends and Regional Differences

Global deaths attributable to high alcohol use doubled between 1990 and 2021, though age-standardized mortality rates have declined in some regions due to improvements in overall healthcare.[27] Eastern Europe continues to experience the highest burden of alcohol-related CVD, while regions like Southeast Asia are seeing dramatic increases in years of life lost (DALYs) due to rising consumption levels.[27]

Genetic Variability and Population Differences

Individual responses to alcohol are not uniform and are profoundly shaped by genetics and baseline health status.[5-7]

Genetic Markers of Sensitivity

The ADH1B (rs1229984) and ALDH2 (rs671) variants are the most studied genetic determinants of alcohol-related cardiovascular risk.[3-7]

• ADH1B (rs1229984): Individuals with this variant metabolize ethanol to acetaldehyde more quickly, leading to higher levels of this toxin and generally lower alcohol consumption. These individuals consistently show a lower risk of CHD and stroke in MR studies, regardless of their self-reported intake.[3,4]
• ALDH2 (rs671): This variant, prevalent in East Asians, impairs the clearance of acetaldehyde. Carriers who continue to drink heavily have a markedly increased risk of ischemic stroke and coronary 動脈動脈は、心臓から全身へ血液を送り出す血管です。. disease compared to non-carriers.[5-7]

Sex-Specific Differences

Women often experience higher blood alcohol concentrations for a given dose compared to men, due to lower levels of gastric alcohol dehydrogenase and a smaller volume of distribution for ethanol.[2] While observational data suggest a J-shaped curve for AF in women, the linear risk in men appears more robustly established.[12,15] Furthermore, heavy consumption increases breast cancer risk in women even at low levels, complicating the risk-benefit analysis of “moderate” drinking.[1]

Risk-Benefit Analysis and Current Guidelines

The debate over whether any level of alcohol is “safe” has reached a critical juncture.[19,20] Current recommendations from major health organizations emphasize caution and personal risk assessment.[13,19]

Comparing Professional Guidelines (2024-2025)

The American Heart Association (AHA), American College of Cardiology (ACC), and the World Health Organization (WHO) have increasingly harmonized their messages, shifting away from endorsing moderate alcohol for health benefits.[13,19]

Organization	Key Recommendation	“Safe” Threshold
American Heart Association	If you don’t drink, don’t start. Limit intake if you do.	Men: <= 2; Women: <= 1 drink/day
World Health Organization	No level of alcohol is completely safe for health.	No recommended consumption level
Dietary Guidelines (US)	Choice not to drink is healthiest. Drink in moderation.	Men: <= 2; Women: <= 1 drink/day
ACC (High Blood Pressure)	Reducing intake is an effective treatment for HBP.	Abstinence or strict moderation

Net Clinical Benefit vs. Cancer Risk

A significant factor in the changing perception of alcohol is the strong evidence linking it to various cancers, including those of the mouth, throat, esophagus, liver, and breast.[1,19] The International Agency for Research on Cancer classifies alcohol as a Group 1 carcinogen.[1] For many individuals, the marginal (and potentially non-causal) cardiovascular benefit of one drink per day is outweighed by the lifelong cumulative increase in cancer risk.[1,19]

Clinical Synthesis and Evidence-Based Conclusion

The comprehensive evaluation of the cardiovascular effects of alcohol reveals a complex landscape where observational benefits are increasingly at odds with genetic and causal inference data.[1,3,4]

1. Dose-Response Summary: While observational studies continue to produce J-shaped curves for myocardial infarction and ischemic stroke, newer genetic methodologies (Mendelian randomization) suggest these benefits may be artifacts of confounding and lifestyle factors.[1,3,4] In contrast, the risks for hypertension, atrial fibrillation, and hemorrhagic stroke appear to increase linearly or exponentially with consumption.[3,4,12,15]
2. Atherosclerosis and Mechanisms: Alcohol increases HDL cholesterol and decreases fibrinogen, but these changes do not consistently result in reduced structural atherosclerosis as measured by arterial imaging.[2,10,11] Heavy intake remains a primary driver of vascular damage and systemic inflammation.[2]
3. Arrhythmic Impact: There is no clear safe threshold for alcohol regarding atrial fibrillation.[12,15] Alcohol induces both acute electrical changes and chronic structural remodeling (心房線維化Microscopic scarring of atrial muscle tissue, often resulting from chronic mechanical stretch or inflammation; fibrosis disrupts normal electrical conduction and is a well-established predictor of AF recurrence after ablation.) that increase the burden of arrhythmias.[12,28,29,31]
4. Stroke Subtypes: A critical dichotomy exists between ischemic and hemorrhagic stroke.[1,23] Any anti-thrombotic benefit for ischemic stroke is counteracted by the significant increase in hemorrhagic risk, particularly during binge drinking or in individuals with pre-existing hypertension.[1,2,23]
5. Beverage Type: The perceived superiority of red wine is likely a reflection of the “healthy user” profile of wine drinkers rather than a unique pharmacological property of wine polyphenols.[18,22] Ethanol itself remains the primary active agent influencing cardiovascular outcomes.[2]
6. Cardiomyopathy: Chronic heavy drinking (80g/day) is a preventable cause of heart failure.[14,15] ACM is uniquely characterized by its potential for reversibility upon total abstinence.[15,25]

The evidence-based conclusion is that while low-to-moderate alcohol consumption may be statistically associated with certain lower cardiovascular risks in observational cohorts, the benefit is likely overstated and may be non-causal.[1,3,4] High consumption and binge drinking clearly cause substantial harm to cardiac structure and function.[2,12,14,15] From a public health and clinical management perspective, the safest level of consumption is low or zero, especially for populations at high risk for arrhythmias, stroke, or cancer.[1,19] Patients should be counseled that if they do not currently consume alcohol, there is no evidence-based reason to start for “heart health.”[19] Those who do drink should be advised to remain strictly within the limits of one drink per day for women and two for men, with frequent alcohol-free days to mitigate the risk of cumulative structural damage.[19]

参考文献

1. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Food and Nutrition Board; Committee on Review of Evidence on Alcohol and Health, Stone KB, Calonge BN, eds. Review of Evidence on Alcohol and Health. Washington (DC): National Academies Press (US); April 23, 2025.
2. Piano MR. Alcohol’s Effects on the Cardiovascular System. Alcohol Res. 2017;38(2):219-241. doi:10.35946/arcr.v38.2.06
3. Larsson SC, Burgess S, Mason AM, Michaëlsson K. Alcohol Consumption and Cardiovascular Disease: A Mendelian Randomization Study. Circ Genom Precis Med. 2020;13(3):e002814. doi:10.1161/CIRCGEN.119.002814
4. Chien PS, Wong TJ, Tai AS, Shr YH, Yu T. Examining the causal association between moderate alcohol consumption and cardiovascular risk factors in the Taiwan Biobank: a Mendelian randomization analysis. Front Cardiovasc Med. 2024;11:1456777. Published 2024 Oct 2. doi:10.3389/fcvm.2024.1456777
5. Tadokoro T, Oura K, Nakahara M, et al. Genetic Polymorphisms of ALDH2 and ADH1B in Alcohol-Induced Liver Injury: Molecular Mechanisms of Inflammation and Disease Progression in East Asian Populations. Int J Mol Sci. 2025;26(17):8328. Published 2025 Aug 28. doi:10.3390/ijms26178328
6. Li YY, Wang H, Wu JJ, et al. ALDH2 gene G487A polymorphism and coronary artery disease: a meta-analysis including 5644 participants. J Cell Mol Med. 2018;22(3):1666-1674. doi:10.1111/jcmm.13443
7. Sung YF, Lee JT, Hu CJ, Jeng JS, Chiou HY, Peng GS. Impact of ALDH2 genotypes and alcohol consumption on age at first-ever ischemic stroke: A cohort study in Taiwan. Alcohol Clin Exp Res (Hoboken). 2026;50(1):e70217. doi:10.1111/acer.70217
8. Centers for Disease Control and Prevention. About moderate alcohol use. CDC website. Published 2025. https://www.cdc.gov/alcohol/about-alcohol-use/moderate-alcohol-use.html
9. Jiang H, Mei X, Jiang Y, et al. Alcohol consumption and atrial fibrillation risk: An updated dose-response meta-analysis of over 10 million participants. Front Cardiovasc Med. 2022;9:979982. Published 2022 Sep 30. doi:10.3389/fcvm.2022.979982
10. Britton AR, Grobbee DE, den Ruijter HM, et al. Alcohol Consumption and Common Carotid Intima-Media Thickness: The USE-IMT Study. Alcohol Alcohol. 2017;52(4):483-486. doi:10.1093/alcalc/agx028
11. Dahlin Almevall A, Wennberg P, Nyman E, et al. Low to moderate alcohol consumption across two decades and subclinical atherosclerosis at age 60: findings from the Northern Sweden Västerbotten Intervention Programme-visualisation of atherosclerosis (VIPVIZA) study. Front Cardiovasc Med. 2026;12:1710165. Published 2026 Jan 7. doi:10.3389/fcvm.2025.1710165
12. Surma S, Lip GYH. Alcohol and Atrial Fibrillation. Rev Cardiovasc Med. 2023;24(3):73. Published 2023 Mar 1. doi:10.31083/j.rcm2403073
13. Gulati, M, Moore, M, Cibotti-Sun, M. 2025 High Blood Pressure Guideline-at-a-Glance. JACC. 2025 Nov, 86 (18) 1560–1566. https://doi.org/10.1016/j.jacc.2025.07.010
14. Shaaban A, Gangwani MK, Pendela VS, et al. Alcoholic Cardiomyopathy. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513322/
15. Domínguez F, Adler E, García-Pavía P. Alcoholic cardiomyopathy: an update. Eur Heart J. 2024;45(26):2294-2305. doi:10.1093/eurheartj/ehae362
16. Harvard T.H. Chan School of Public Health. Is wine fine, or beer better? The Nutrition Source. https://nutritionsource.hsph.harvard.edu/is-wine-fine-or-beer-better/
17. Institute for Health Metrics and Evaluation. Alcohol use. IHME website. https://www.healthdata.org/research-analysis/health-topics/alcohol-use
18. Lucerón-Lucas-Torres M, Saz-Lara A, Díez-Fernández A, et al. Association between Wine Consumption with Cardiovascular Disease and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(12):2785. Published 2023 Jun 17. doi:10.3390/nu15122785
19. Piano MR, Marcus GM, Aycock DM, et al. Alcohol Use and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2025;152(1):e7-e21. doi:10.1161/CIR.0000000000001341
20. Rolver MG, Emanuelsson F, Nordestgaard BG, Benn M. C-reactive protein and prospective cardiometabolic risk: observational and Mendelian randomization study of ischemic stroke and all-cause death. Cardiovasc Diabetol. 2025;25(1):11. Published 2025 Dec 11. doi:10.1186/s12933-025-03028-5
21. Bekkevold OJ, Damås JK, Brumpton BM, Åsvold BO. The causal role of C-reactive protein and interleukin-6 on anxiety and depression symptoms and life satisfaction: Mendelian randomisation analyses in the HUNT study. Psychol Med. 2023;53(16):7561-7568. doi:10.1017/S0033291723001290
22. Li H, Förstermann U. Red wine and cardiovascular health. Circ Res. 2012;111(8):959-961. doi:10.1161/CIRCRESAHA.112.278705
23. Toubasi AA, Al-Sayegh TN. Alcohol Use and Types and Ischemic Stroke: A Systematic Review and Meta-Analysis. Eur Neurol. 2025;88(3-4):140-150. doi:10.1159/000547945
24. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319(7224):1523-1528. doi:10.1136/bmj.319.7224.1523
25. Estruch R, Fernández-Solá J, Mont L, et al. Reversibilidad de la miocardiopatía alcohólica con la abstinencia: presentación de dos casos [Reversibility of alcoholic myocardiopathy with abstinence: presentation of 2 cases]. Med Clin (Barc). 1989;92(2):69-71.
26. Howie EK, Sui X, Lee DC, Hooker SP, Hébert JR, Blair SN. Alcohol consumption and risk of all-cause and cardiovascular disease mortality in men. J Aging Res. 2011;2011:805062. doi:10.4061/2011/805062
27. Niu C, Dong J, Zhang P, et al. The global burden of cardiovascular disease attributable to high alcohol use from 1990 to 2021: an analysis for the global burden of disease study 2021. Front Public Health. 2025;13:1541641. Published 2025 Feb 14. doi:10.3389/fpubh.2025.1541641
28. Qiao Y, Shi R, Hou B, et al. Impact of Alcohol Consumption on Substrate Remodeling and Ablation Outcome of Paroxysmal Atrial Fibrillation. J Am Heart Assoc. 2015;4(11):e002349. Published 2015 Nov 9. doi:10.1161/JAHA.115.002349
29. Huang Z, Luo C, Wu Z, Zheng B. Electrophysiological Mechanisms and Therapeutic Potential of Calcium Channels in Atrial Fibrillation. Rev Cardiovasc Med. 2025;26(6):33507. Published 2025 Jun 25. doi:10.31083/RCM33507